Synthesis and preliminary biological evaluation of radiolabeled 5-BDBD analogs as new candidate PET radioligands for P2X4 receptor

Publication date: Available online 18 May 2017
Source:Bioorganic & Medicinal Chemistry
Author(s): Min Wang, Mingzhang Gao, Jill A. Meyer, Jonathan S. Peters, Hamideh Zarrinmayeh, Paul R. Territo, Gary D. Hutchins, Qi-Huang Zheng
P2X4 receptor has become an interesting molecular target for treatment and PET imaging of neuroinflammation and associated brain diseases such as Alzheimer's disease. This study reports the first design, synthesis, radiolabeling and biological evaluation of new candidate PET P2X4 receptor radioligands using 5-BDBD, a specific P2X4 receptor antagonist, as a scaffold. 5-(3-Hydroxyphenyl)-1-[¹¹C]methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (N-[¹¹C]Me-5-BDBD analog, [¹¹C]9) and 5-(3-Bromophenyl)-1-[¹¹C]methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (N-[¹¹C]Me-5-BDBD, [¹¹C]8c) were prepared from their corresponding desmethylated precursors with [¹¹C]CH3OTf through N-[¹¹C]methylation and isolated by HPLC combined with SPE in 30-50% decay corrected radiochemical yields with 370-1110 GBq/µmol specific activity at EOB. 5-(3-[¹⁸F]Fluorophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one ([¹⁸F]F-5-BDBD, [¹⁸F]5a) and 5-(3-(2-[¹⁸F]fluoroethoxy)phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one ([¹⁸F]FE-5-BDBD, [¹⁸F]11) were prepared from their corresponding nitro- and tosylated precursors by nucleophilic substitution with K[¹⁸F]F/Kryptofix 2.2.2 and isolated by HPLC-SPE in 5-25% decay corrected radiochemical yields with 111-740 GBq/µmol specific activity at EOB. The preliminary biological evaluation of radiolabeled 5-BDBD analogs indicated these new radioligands have similar biological activity with their parent compound 5-BDBD.

Graphical abstract

http://ift.tt/2qDsiFp